Climb Bio Stock Earnings Per Share

CLYM Stock   1.95  0.08  3.94%   
Climb Bio fundamentals help investors to digest information that contributes to Climb Bio's financial success or failures. It also enables traders to predict the movement of Climb Stock. The fundamental analysis module provides a way to measure Climb Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Climb Bio stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Climb Bio Company Earnings Per Share Analysis

Climb Bio's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Earnings per Share

 = 

Earnings

Average Shares

More About Earnings Per Share | All Equity Analysis

Climb Earnings Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Climb Bio is extremely important. It helps to project a fair market value of Climb Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Climb Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Climb Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Climb Bio's interrelated accounts and indicators.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Competition

Climb Common Stock Shares Outstanding

Common Stock Shares Outstanding

28.59 Million

At this time, Climb Bio's Common Stock Shares Outstanding is very stable compared to the past year.
According to the company disclosure, Climb Bio has an Earnings Per Share of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The earnings per share for all United States stocks is 100.0% higher than that of the company.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module

Climb Fundamentals

Net Income(35.12 M)
Total Debt2.87 M
Total Asset110.47 M
Retained Earnings(155.98 M)
Working Capital107.42 M
Net Asset110.47 M

About Climb Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Climb Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Climb Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Climb Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Climb Bio is a strong investment it is important to analyze Climb Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Climb Bio's future performance. For an informed investment choice regarding Climb Stock, refer to the following important reports:
Check out Climb Bio Piotroski F Score and Climb Bio Altman Z Score analysis.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.